Skip to main content

Advertisement

Table 1 Baseline characteristics of children at enrolment in a clinical trial of the efficacy of three artemisinin-containing combinations therapies with amodiaquine + sulphadoxine–pyrimathamine (AQ-SP)

From: Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial

  AS-SMP AS-AQ AL AQ-SP p
N = 58 N = 68 N = 60 N = 65
Age (months)      0.396
Median 43 34 40 36  
Interquartile range 27-51 25-49 27-48 23-52
Minimum, maximum 7-59 7-59 3-58 2-59  
Gender      0.235
Male (n (%)) 27 (47%) 39 (57%) 38 (63%) 32 (49%)  
P. falciparum(/μl)      0.853
Median 17 000 18 509 16 471 14 400  
Interquartile range 8200-60 000 6480-9 814 7200-58917 8000-36 000
Temperature at day 0 (°C)      0.198
Median 38,7 38.9 39.2 39.1  
Interquartile range 38.3-39.7 38.3-39.9 38.4-40.2 38.4-39.7
  1. AS-SMP, Artesunate + sulphamethoxypyrazine-pyrimethamine (Coarinate®); AS-AQ, Artesunate + amodiaquine (Coarsucam®); AL, Artemether + lumefantrine (Coartem®); AQ + SP, Amodiaquine + sulphadoxine-pyrimethamine; N, Effective number.